A Victim Of Its Own Success? U-Turn On Taro Merger Could Be A Strategic Call By India’s Sun Pharma
This article was originally published in PharmAsia News
Executive Summary
Taro’s strong performance since Sun took a majority stake has complicated the Indian pharma’s merger plans, but analysts say the story may still evolve.